SOPH
NASDAQ
$6.33
SOPHiA Genetics SA (SOPH)
Sophia Genetics SA (SOPH) stands at the forefront of data-driven medicine, delivering advanced genomic and clinical data analytics that significantly enhance patient outcomes. Utilizing cutting-edge machine learning technologies, the company provides an integrated platform designed to help healthcare providers navigate complex genomic data, facilitating personalized treatment strategies in oncology, rare diseases, and hereditary conditions. With a robust global footprint and strategic partnerships with leading healthcare organizations, Sophia Genetics is well-positioned to transform the precision medicine landscape and solidify its role as a key player in the genomics industry.
Sector:
Healthcare
Industry:
Health Information Services
Buy
Target: $8 (+26.38%)
Market Cap
$410M
Revenue 5Y CAGR
+22.12%
Free Cash Flow Yield
-11.07%
Beta (5Y)
0.97
Price Chart
Valuation
Market Cap$410M
P/S5.96
P/B10.43
Profitability
Total Revenue (TTM)$81M
Gross Profit (TTM)$55M
EBITDA-$66M
Profit Margin-89.1%
Operating Margin-79.7%
EPS-$1.18
Financial Health
Debt-to-Equity136.6%
Free Cash Flow Yield-11.07%
Growth & Risk
EPS 5Y CAGR+6.46%
Revenue 5Y CAGR+22.12%
FCF 5Y CAGR+3.56%
Beta (5Y)0.97
Sharpe Ratio1.06